NanoViricides Inc (NNVC) Short Interest Update

NanoViricides Inc (NYSEAMERICAN:NNVC) was the recipient of a significant drop in short interest in December. As of December 29th, there was short interest totalling 459,345 shares, a drop of 44.7% from the December 15th total of 830,252 shares. Approximately 0.9% of the company’s stock are short sold. Based on an average trading volume of 186,490 shares, the days-to-cover ratio is currently 2.5 days.

Shares of NanoViricides (NYSEAMERICAN:NNVC) opened at $0.90 on Friday. NanoViricides has a 12-month low of $0.83 and a 12-month high of $1.64. The company has a market capitalization of $57.00, a price-to-earnings ratio of -6.00 and a beta of 0.21.

NanoViricides (NYSEAMERICAN:NNVC) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.03) EPS for the quarter.

Separately, BidaskClub downgraded NanoViricides from a “sell” rating to a “strong sell” rating in a report on Saturday, November 4th.

TRADEMARK VIOLATION WARNING: “NanoViricides Inc (NNVC) Short Interest Update” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thestockobserver.com/2018/01/14/nanoviricides-inc-nnvc-short-interest-update-2.html.

NanoViricides Company Profile

NanoViricides, Inc is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases.

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply